Efruxifermin clinical trials
Also written AMG 876.
How each study uses efruxifermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the efruxifermin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses efruxifermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisRecruitingPhase 3Akero Therapeutics, IncNCT06215716Written as Efruxifermin
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHRecruitingPhase 3Akero Therapeutics, IncNCT06528314Written as Efruxifermin
- A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Active, not recruitingPhase 3Akero Therapeutics, IncNCT06161571Written as Efruxifermin
- A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Akero Therapeutics, IncNCT04767529Written as Efruxifermin
- Multiple Ascending Dose Study in Subjects With Type 2 DiabetesTerminatedPhase 1AmgenNCT01856881Written as AMG 876
- Single Ascending Dose Trial in Patients With Type 2 DiabetesTerminatedPhase 1AmgenNCT01492465Written as AMG 876
Codes
What other systems call efruxifermin · ClinicalTrials.gg INT002145
- MeSH (NLM) C000731827efruxiferminOne source NLM
- UNII (FDA) C1KR8TZ3NEEFRUXIFERMINConfirmed FDA, NLM
- NCI Thesaurus C175776EfruxiferminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731827 | efruxifermin | One source NLM |
| UNII (FDA) | C1KR8TZ3NE | EFRUXIFERMIN | Confirmed FDA, NLM |
| NCI Thesaurus | C175776 | Efruxifermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.